Copyright
©The Author(s) 2025.
World J Hepatol. Dec 27, 2025; 17(12): 113359
Published online Dec 27, 2025. doi: 10.4254/wjh.v17.i12.113359
Published online Dec 27, 2025. doi: 10.4254/wjh.v17.i12.113359
Table 1 Baseline characteristics of the study cohort, median (interquartile range)
| Total (n = 30) | Control (n = 14) | NAFLD (n = 16) | P value |
| Age, years | 15.09 (13.27-17.85) | 15.97 (14.42-17.88) | 0.1661 |
| BMI (kg/m2) | 20.91 (18.85-23.21) | 31.14 (28.52-33.59) | < 0.0001a |
| BMI z-score | 0.5950 (0.1350-1.080) | 2.555 (2.295-2.955) | < 0.0001a |
| ALT (U/L) | 13.00 (12.00-17.00) | 43.00 (27.25-94.00) | < 0.0001a |
| AST (U/L) | 15.00 (12.00-20.00) | 32.00 (22.00-41.00) | 0.0004a |
| Total bilirubin (mg/dL) | 0.6600 (0.5000-2.340) | 0.6100 (0.4200-0.9100) | 0.2866 |
| GGTP (U/L) | 21.50 (15.50-23.50) | 30.50 (19.00-50.25) | 0.1181 |
| TC (mg/dL) | 157.0 (133.0-171.0) | 149.0 (139.8-179.0) | 0.8366 |
| LDL-C (mg/dL) | 96.00 (63.60-107.5) | 88.50 (71.25-97.00) | 0.5315 |
| HDL-C (mg/dL) | 53.00 (49.00-54.00) | 35.00 (31.50-40.00) | < 0.0001a |
| TG (mg/dL) | 67.50 (58.50-86.50) | 161.5 (100.5-239.0) | 0.0005a |
| Glucose (mg/dL) | 86.70 (84.05-88.15) | 88.90 (82.90-94.10) | 0.1846 |
| Insulin (mU/mL) | 12.80 (9.013-13.98) | 13.87 (9.600-23.33) | 0.2750 |
| HOMA-IR | 2.77 (1.870-2,975) | 3.010 (2.190-5.470) | 0.1995 |
| Systolic pressure (mmHg) | 121.0 (111.3-125.0) | 120.0 (112.5-127.5) | 0.9904 |
| Diastolic pressure | 67.00 (58.50-75.50) | 70.00 (63.00-75.50) | 0.5645 |
| Urea (mg/dL) | 26.90 (21.70-35.41) | 22.50 (18.10-27.50) | 0.3301 |
| Ammonaemia (μmol/L) | 61.20 (52.65-72.25) | 495.4 (349.6-631.8) | < 0.0001a |
Table 2 Two-factor interaction model analysis (non-alcoholic fatty liver disease × fecal extract stimulation)
- Citation: Zeber-Lubecka N, Michalkiewicz J, Dabrowska M, Goryca K, Wierzbicka-Rucińska A, Jańczyk W, Jankowska I, Świąder-Leśniak A, Kubiszewska I, Ziemska-Legięcka J, Socha P, Ostrowski J. Transcriptome profiles of peripheral blood mononuclear cells differentiate male adolescents with non-alcoholic fatty liver disease from healthy peers. World J Hepatol 2025; 17(12): 113359
- URL: https://www.wjgnet.com/1948-5182/full/v17/i12/113359.htm
- DOI: https://dx.doi.org/10.4254/wjh.v17.i12.113359
